With the transformation complete, ALK is entering the next phase of its development. The challenge now is to use what has been achieved as the launchpad for future success as ALK seeks to become the allergy company by extending its leadership in respiratory allergy, establishing a presence in food allergy, expanding its position in anaphylaxis, and pursuing new innovations through research.

CEO Carsten Hellmann said: “With the next phase of ALK’s development, we will deliver further sustainable growth, while increasing the EBIT-margin until we reach our goal of ~25% in 2025, thus generating attractive shareholder returns. Tablets will remain the primary growth driver for the foreseeable future, but we are also introducing initiatives with the potential to accelerate growth within five-to-10 years and make ALK a much larger company and become a true global allergy leader.”

The emphasis for the period 2021-23 is on achieving sustainable growth and increasing profitability following the significant investments made to successfully deliver the transformation.

ALK’s overall strategy remains unchanged, and is still anchored in the same four areas of focus, albeit with minor adjustments to some of the names to reflect the necessary steps to achieving profitability:

• Succeed in North America 
• Complete and commercialise the tablet portfolio 
• Consumer engagement and new horizons 
• Optimise for excellence

In addition, some longer-term initiatives have been introduced which, as they develop, are designed to provide the additional impetus to accelerate ALK towards its longer-term aspiration of becoming a global allergy leader.